vs
Apellis Pharmaceuticals, Inc.（APLS）与简柏特（REXR）财务数据对比。点击上方公司名可切换其他公司
简柏特的季度营收约是Apellis Pharmaceuticals, Inc.的1.2倍（$245.1M vs $199.9M），简柏特净利率更高（0.5% vs -29.5%，领先30.0%），简柏特同比增速更快（-2.9% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
简柏特是全球知名的信息技术服务、咨询及外包提供商，成立于印度古尔冈，注册地为百慕大，总部设于美国纽约。目前全球员工超12.5万人，服务覆盖30余个国家，于纽交所上市，2023年营收达44.8亿美元。
APLS vs REXR — 直观对比
营收规模更大
REXR
是对方的1.2倍
$199.9M
营收增速更快
REXR
高出3.1%
-5.9%
净利率更高
REXR
高出30.0%
-29.5%
两年增速更快
APLS
近两年复合增速
1.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $245.1M |
| 净利润 | $-59.0M | $1.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 41.0% |
| 净利率 | -29.5% | 0.5% |
| 营收同比 | -5.9% | -2.9% |
| 净利润同比 | -62.2% | 27.7% |
| 每股收益（稀释后） | $-0.40 | $0.38 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSREXR
| Q1 26 | — | $245.1M | ||
| Q4 25 | $199.9M | $248.1M | ||
| Q3 25 | $458.6M | $253.2M | ||
| Q2 25 | $178.5M | $249.5M | ||
| Q1 25 | $166.8M | $252.3M | ||
| Q4 24 | $212.5M | $242.9M | ||
| Q3 24 | $196.8M | $241.8M | ||
| Q2 24 | $199.7M | $237.6M |
净利润APLSREXR
| Q1 26 | — | $1.2M | ||
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $89.9M | ||
| Q2 25 | $-42.2M | $116.3M | ||
| Q1 25 | $-92.2M | $71.2M | ||
| Q4 24 | $-36.4M | $64.9M | ||
| Q3 24 | $-57.4M | $67.8M | ||
| Q2 24 | $-37.7M | $82.5M |
营业利润率APLSREXR
| Q1 26 | — | 41.0% | ||
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | — | ||
| Q2 25 | -18.6% | — | ||
| Q1 25 | -50.0% | — | ||
| Q4 24 | -12.3% | — | ||
| Q3 24 | -24.0% | — | ||
| Q2 24 | -14.7% | — |
净利率APLSREXR
| Q1 26 | — | 0.5% | ||
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 35.5% | ||
| Q2 25 | -23.6% | 46.6% | ||
| Q1 25 | -55.3% | 28.2% | ||
| Q4 24 | -17.1% | 26.7% | ||
| Q3 24 | -29.2% | 28.0% | ||
| Q2 24 | -18.9% | 34.7% |
每股收益（稀释后）APLSREXR
| Q1 26 | — | $0.38 | ||
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.37 | ||
| Q2 25 | $-0.33 | $0.48 | ||
| Q1 25 | $-0.74 | $0.30 | ||
| Q4 24 | $-0.30 | $0.26 | ||
| Q3 24 | $-0.46 | $0.30 | ||
| Q2 24 | $-0.30 | $0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $51.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $8.3B |
| 总资产 | $1.1B | $12.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSREXR
| Q1 26 | — | $51.7M | ||
| Q4 25 | $466.2M | $165.8M | ||
| Q3 25 | $479.2M | $249.0M | ||
| Q2 25 | $370.0M | $431.1M | ||
| Q1 25 | $358.4M | $504.6M | ||
| Q4 24 | $411.3M | $56.0M | ||
| Q3 24 | $396.9M | $61.8M | ||
| Q2 24 | $360.1M | $125.7M |
总债务APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | — | $3.3B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | — | $3.3B | ||
| Q1 25 | — | $3.3B | ||
| Q4 24 | — | $3.3B | ||
| Q3 24 | — | $3.4B | ||
| Q2 24 | — | $3.3B |
股东权益APLSREXR
| Q1 26 | — | $8.3B | ||
| Q4 25 | $370.1M | $8.5B | ||
| Q3 25 | $401.2M | $8.7B | ||
| Q2 25 | $156.3M | $8.8B | ||
| Q1 25 | $164.2M | $8.8B | ||
| Q4 24 | $228.5M | $8.3B | ||
| Q3 24 | $237.1M | $8.1B | ||
| Q2 24 | $264.3M | $8.0B |
总资产APLSREXR
| Q1 26 | — | $12.4B | ||
| Q4 25 | $1.1B | $12.6B | ||
| Q3 25 | $1.1B | $12.9B | ||
| Q2 25 | $821.4M | $13.1B | ||
| Q1 25 | $807.3M | $13.1B | ||
| Q4 24 | $885.1M | $12.6B | ||
| Q3 24 | $901.9M | $12.4B | ||
| Q2 24 | $904.5M | $12.4B |
负债/权益比APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.38× | ||
| Q3 25 | — | 0.37× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.38× | ||
| Q4 24 | — | 0.40× | ||
| Q3 24 | — | 0.42× | ||
| Q2 24 | — | 0.42× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $542.1M | ||
| Q3 25 | $108.5M | $149.6M | ||
| Q2 25 | $4.4M | $128.2M | ||
| Q1 25 | $-53.4M | $152.6M | ||
| Q4 24 | $19.4M | $478.9M | ||
| Q3 24 | $34.1M | $127.2M | ||
| Q2 24 | $-8.3M | $101.7M |
自由现金流APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $208.7M | ||
| Q3 25 | $108.3M | $60.5M | ||
| Q2 25 | $4.4M | $45.0M | ||
| Q1 25 | $-53.4M | $73.4M | ||
| Q4 24 | $19.3M | $105.5M | ||
| Q3 24 | — | $7.2M | ||
| Q2 24 | $-8.4M | $16.5M |
自由现金流率APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 84.1% | ||
| Q3 25 | 23.6% | 23.9% | ||
| Q2 25 | 2.5% | 18.0% | ||
| Q1 25 | -32.0% | 29.1% | ||
| Q4 24 | 9.1% | 43.4% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | -4.2% | 7.0% |
资本支出强度APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 134.4% | ||
| Q3 25 | 0.0% | 35.2% | ||
| Q2 25 | 0.0% | 33.3% | ||
| Q1 25 | 0.0% | 31.4% | ||
| Q4 24 | 0.0% | 153.7% | ||
| Q3 24 | 0.0% | 49.6% | ||
| Q2 24 | 0.0% | 35.8% |
现金转化率APLSREXR
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 1.66× | ||
| Q2 25 | — | 1.10× | ||
| Q1 25 | — | 2.14× | ||
| Q4 24 | — | 7.38× | ||
| Q3 24 | — | 1.88× | ||
| Q2 24 | — | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
REXR
暂无分部数据
